About the ABPI

The ABPI represents innovative resea​rch-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.

Globally our industry is researching and developing more than 7,000 new medicines.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.​​​​​​​

Welcome to the Future of Medicine is available to view through YouTube here and for free third-party use.

A teaser for the experience is available online here.

Gene editing and gene therapies: Gene therapies offer a potential life change for patients with haemophilia B. Around 8,000 people in Europe have haemophilia B, of which 60% live with a severe form of the disease, putting them at risk of bleeds. Gene therapy Phase I/II trials have seen results sufficient to transform the disease into a mild form, while further trials could see a cure. Read more.

Diagnostics sensors: Scientists at Northeastern University in Boston, Massachusetts have been investigating the benefits of using carbon nanosensors. Read more.

3D printing of medicine patches University of Kent PhD students are researching 3D print applications for transdermal drug delivery. Read more.

Media enquiries


+44 (0) 20 7747 7147​​